The Herbal Medicine Containing of Ivy Leaf Dry Extract in the Treatment of Productive Cough in Children

Olszanecka-Glinianowicz, Magdalena; Doniec, Zbigniew; Schönknecht, Karina; Almgren-Rachtan, Agnieszka

doi:10.36740/wlek202004108

Cited by 13 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Horehound owers (Marrubium vulgare L.) have also been traditionally used in Europe as well as in Southern and Eastern Mediterranean countries, and one of their therapeutic uses is treatment of respiratory diseases [15]. Ivy leaves (Hedera helix L.) showed effectiveness for treating symptoms of respiratory tract infections and improving the respiratory function, mainly for paediatric coughs, by reducing their frequency and intensity, with high tolerability [16][17][18][19][20]. Finally, sundew owers (Drosera rotundifolia L.) have a long history as a remedy for coughs, being probably one of the most widely distributed carnivorous plant species [21].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and tolerability of SEDIFLÙ® in treating dry or productive cough in the paediatric population (SEPEDIA). A pilot, randomized, double blind, placebo-controlled, multicentre clinical trial.

Núñez¹,

Chiatti²,

Tansella

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Nonpharmacological interventions, such as throat and pharynx demulcents and emollients, are an alternative for cough management and mucosa protection, especially in children, who experience upper respiratory infection-associated acute cough almost four times more than adults. The aim of this trial was to assess the effectiveness of Sediflù®, a medical device containing active herbal ingredients, on nocturnal and diurnal persistent coughs in children, with a duration of 3 to 7 days. Methods: Children with a dry and/or productive cough were enrolled in this prospective, interventional, multicentre, placebo-controlled, double-blind, randomized clinical study. Clinical efficacy was assessed through the evaluation of the soothing action of Sediflù® against dry and/or productive coughing, both at night and during the day and other effects of coughing associated with quality of sleep: frequency, child’s quality of sleep, parental quality of sleep, severity and bothersomeness. Results: Treatment with Sediflù® improved both night- and day-time cough scores from D2. The improvement of the night-time cough score is statistically significantly higher in the Sediflù® group (28% and 71% lower) at D4 and D7, respectively, in comparison to the placebo group (p<0.05). The diurnal score improved significantly in the Sediflù® group (22% and 71% lower) at D3 and D7, respectively, in comparison to the placebo group (p<0.05 and p<0.01, respectively). There was also a significant decrease in the scores of five nocturnal variables associated with sleep quality (frequency, severity, bothersomeness, child’s and parental quality of sleep) from D2, and it was maintained throughout the rest of the days (D3-D7). Considering the inter-group analysis, Sediflù® showed a more significant improvement for frequency, severity, bothersomeness, child’s and parental quality of sleep (70%, 51%, 52%, 58% and 66% lower, respectively) at D7, in comparison to the placebo group (p<0.01). The analysis of a subgroup of children, with cough scores ≥ 3, showed a significant reduction of both frequency and severity scores from the first day of treatment with Sediflù® (p<0.05). Conclusions: Sediflù® syrup can be considered a valid treatment for cough management, especially in younger children with upper respiratory tract infections, shortening the cough duration in children, with a very good safety profile. Trial registration: NEOPS-AEMPS, NEOPS Num 20-0040, Registered 22 December 2020, https://neops.aemps.es/

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and tolerability of SEDIFLÙ® in treating dry or productive cough in the paediatric population (SEPEDIA). A pilot, randomized, double blind, placebo-controlled, multicentre clinical trial.

Núñez¹,

Chiatti²,

Tansella

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…В другом исследовании была показана эффективность фитопрепарата, содержащего экстракт листьев плюща, применяемого два раза в день у детей с продуктивным кашлем, также была отмечена удовлетворенность лечением родителей [1]. Многоцентровое обсервационное исследование было проведено 268 врачами, работающими в сфере первичной медико-санитарной помощи.…”

Section: растительные препараты в лечении кашляunclassified

“…Использование фитотерапии, содержащей экстракт листьев плюща обыкновенного, применяемой два раза в день, может быть хорошей альтернативой существующим терапевтическим схемам при лечении продуктивного кашля у детей. Эта рекомендация подтверждается эффективностью, сопоставимой с другими лекарственными средствами, и высоким уровнем удовлетворенности пациентов и их родителей от его применения [1,20,23].…”

Section: растительные препараты в лечении кашляunclassified

“…Его физиологическая роль сводится к очистке дыхательных путей от посторонних веществ и механических препятствий, которые затрудняют процесс дыхания, а также к восстановлению мукоцилиарного транспорта бронхиального секрета (мукоцилиарного клиренса). Кашлевой рефлекс может быть вызван повреждением слизистой оболочки верхних дыхательных путей во время вирусных и бактериальных инфекций, или раздражением нервов, ответственных за проведение импульсов этого рефлекса, или при риносинусите, аденоидите, сопровождаю щихся стеканием слизи по задней стенке глотки (postnasal drip syndrome), или инородным телом в дыхательных путях [1]. Кашлевой рефлекс вызывается вредными раздражителями, которые обнаруживаются рецепторами и ионными каналами, в основном распределенными по всей гортани, глотке, пищеводу, трахее и легочной паренхиме, стимулируют афферентные полимодальные блуждаю щие нервы (C-волокна и A-δ-волокна) к соматосенсорной коре головного мозга, отвечаю щей за кашель.…”

Section: Introductionunclassified

See 1 more Smart Citation

The role of herbal medicines in treating cough in children

et al. 2022

View full text Add to dashboard Cite

The physiological role of cough is to restore mucociliary clearance in the respiratory tract. However, if there are inflammatory changes against the background of a respiratory infection, cough may be non-productive and impair the patient’s quality of life. For a rational choice of drug, the true cause of cough should be determined on the basis of history, physical examination and, if necessary, additional instrumental/laboratory investigations. Modern phytopharmaceuticals are considered effective and safe for cough relief. Herbal medicines contain biologically active substances, which are incorporated into the metabolic processes of the body in a more natural way, in contrast to synthetic analogues. The article focuses on the effectiveness of an ivy leaf extract, which has a complex composition: it contains saponins, flavonoids, glycosides, as well as components of essential oils. Due to its composition, it has several effects: expectorant due to its secretolytic and mucolytic action, and antispasmodic based on the increased sensitivity of β2-adrenoreceptor cells of bronchial smooth muscle cells to endogenous and exogenous stimulation, on reducing intracellular calcium levels and bronchial relaxation. The efficacy of ivy leaf extract has been shown in a total of more than 20 clinical trials, mainly in children suffering from upper respiratory tract infections. Cough treatment aims at changing the rheological properties of the secretion and increasing the effectiveness of the cough. The good compatibility of herbal medicines with other drugs, including antibiotics, allows their use not only as monotherapeutic agents, but also in combination therapy for the treatment of cough in children.

show abstract

“…Лікарські рослини чинять різноманітні ефекти на організм людини. Правильний підбір компонентів і доз у фітотерапії має важливе значення [24,47,52,56].…”

Section: результатиunclassified

Phytotherapy for respiratory diseases: past and present. Review

Федів¹,

Багрій²,

Волошина³

et al. 2021

УТЖ

View full text Add to dashboard Cite

Acute and chronic respiratory diseases constitute one of the main reasons of death worldwide. Joining coronavirus infection COVID‑19 worsens the course of diseases of the bronchopulmonary system and other systems and organs, in particular, respiratory, cardiovascular, urinary, gastrointestinal and others. There are a number of drugs of natural origin with multifaceted metabolic and multiorgan action, the use of which associated with minimal risks, mainly due to individual intolerance to particular components. Objective. To analyze the current possibilities of phytotherapy of respiratory diseases, including COVID‑19. Materials and methods. The information search has been performed using sources in print and electronic media, scientific tracking databases with application of methods of the analysis, comparison and generalization. Results. Treatment with herbal remedies was established to have better tolerability and lower frequency of side effects and complications. They are characterized with high biological multifaceted activity and a broad therapeutic index. It is believed that the use of herbal medicine in such cases as an adjunct treatment and maintenance therapy is justified. Monotherapy with drugs from individual medicinal plants is not as effective as their combination. The use of extracts of several medicinal plants is more appropriate for long‑term use, the composition, dose, synergism, compliance, minimal side effects and mild therapeutic effect are important. In the pharmaceutical market of Ukraine there are many domestic and imported herbal remedies used in acute and chronic respiratory diseases. One of them is Bronchilor (Biohels International GmbH, Germany), containing extracts of thyme, Iceland moss, primrose and thorny bamboo. The drug has a local antiseptic effect, it forms a protective film on the the bronchopulmonary receptors, enhances the ciliate epithelial activity, and acts as an expectorant. The publications of Chinese scientists indicate the feasibility of using herbal medicine in the acute period of COVID‑19 infection and postcovid syndrome. Conclusions. Modern multicomponent phytotherapeutic agents play an important role in the complex treatment of acute and chronic respiratory diseases. Further studies are required to investigate the use of phytotherapy, in particular, Bronchilor, as a supportive therapy for postcovid rehabilitation in patients with respiratory system injury.

show abstract

The Herbal Medicine Containing of Ivy Leaf Dry Extract in the Treatment of Productive Cough in Children

Cited by 13 publications

References 3 publications

Efficacy and tolerability of SEDIFLÙ® in treating dry or productive cough in the paediatric population (SEPEDIA). A pilot, randomized, double blind, placebo-controlled, multicentre clinical trial.

Efficacy and tolerability of SEDIFLÙ® in treating dry or productive cough in the paediatric population (SEPEDIA). A pilot, randomized, double blind, placebo-controlled, multicentre clinical trial.

The role of herbal medicines in treating cough in children

Phytotherapy for respiratory diseases: past and present. Review

Contact Info

Product

Resources

About